PMID- 30339792
OWN - NLM
STAT- MEDLINE
DCOM- 20200807
LR  - 20211204
IS  - 1531-5053 (Electronic)
IS  - 0278-2391 (Linking)
VI  - 77
IP  - 9
DP  - 2019 Sep
TI  - The Mammalian Target of Rapamycin-70-kDa Ribosomal Protein S6 Kinase Axis 
      Inhibits the Biological Function of Tongue Squamous Cell Carcinoma.
PG  - 1928-1940
LID - S0278-2391(18)31090-5 [pii]
LID - 10.1016/j.joms.2018.09.020 [doi]
AB  - PURPOSE: Studies have shown the mammalian target of rapamycin (mTOR) and 70-kDa 
      ribosomal protein S6 kinase (p70S6K) to be tumor suppressors in many cancers. 
      These factors may have synergistic functions in tongue squamous cell carcinoma 
      (TSCC), which is the most common malignant cancer in the oral region. We aimed to 
      investigate the expression of the mTOR-p70S6K axis in TSCC patients and its 
      biological function in TSCC cell lines. MATERIALS AND METHODS: Sixty-eight TSCC 
      patients were included in this study, and their features, including age, gender, 
      tumor differentiation, lymphatic metastasis, and clinical stage, were recorded. 
      The expression of mTOR and p70S6K was detected by immunohistochemistry. Small 
      interfering RNA constructs were delivered into TSCC cells to downregulate mTOR 
      and p70S6K expression in vitro. After transfection, cell proliferation, migration 
      or invasion, apoptosis, and chemoresistance assays were performed to examine 
      cellular variations of biological function. RESULTS: High expression of the 
      mTOR-p70S6K axis was associated with higher tumor stage, lymph node metastasis, 
      and poor tumor differentiation. Suppression of mTOR and p70S6K in TSCC cells 
      resulted in the inhibition of cell proliferation, metastases, and 
      chemoresistance. Inhibiting mTOR expression could inhibit p70S6K expression but 
      not vice versa. CONCLUSIONS: The high expression of mTOR and p70S6K is closely 
      associated with malignant characterization of TSCC patients, and it could inhibit 
      biological functions of TSCC cell lines. Taken together, the mTOR-p70S6K axis may 
      serve as a potential therapeutic strategy for TSCC.
CI  - Copyright (c) 2018. Published by Elsevier Inc.
FAU - Yi, Chen
AU  - Yi C
AD  - PhD Student, Department of Oral and Maxillofacial Surgery, Sun Yat-sen Memorial 
      Hospital, and Department of Oral and Maxillofacial Surgery, Guanghua School of 
      Stomatology, Hospital of Stomatology, Sun Yat-sen University, Guangzhou, China.
FAU - Huang, Zixian
AU  - Huang Z
AD  - PhD Student, Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics 
      and Gene Regulation and Department of Oral and Maxillofacial Surgery, Sun Yat-sen 
      Memorial Hospital, Sun Yat-sen University, Guangzhou, China.
FAU - Huang, Zhiquan
AU  - Huang Z
AD  - Professor, Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and 
      Gene Regulation and Department of Oral and Maxillofacial Surgery, Sun Yat-sen 
      Memorial Hospital, Sun Yat-sen University, Guangzhou, China.
FAU - Zhao, Xiaopeng
AU  - Zhao X
AD  - Associated Professor, Department of Oral and Maxillofacial Surgery, Sun Yat-sen 
      Memorial Hospital, Sun Yat-sen University, Guangzhou, China.
FAU - Li, Haigang
AU  - Li H
AD  - Professor, Department of Pathology, Sun Yat-sen Memorial Hospital, Sun Yat-sen 
      University, Guangzhou, China.
FAU - Wang, Jianguang
AU  - Wang J
AD  - Professor, Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and 
      Gene Regulation and Department of Oral and Maxillofacial Surgery, Sun Yat-sen 
      Memorial Hospital, Sun Yat-sen University, Guangzhou, China. Electronic address: 
      wjgmin@126.com.
LA  - eng
PT  - Journal Article
DEP - 20180924
PL  - United States
TA  - J Oral Maxillofac Surg
JT  - Journal of oral and maxillofacial surgery : official journal of the American 
      Association of Oral and Maxillofacial Surgeons
JID - 8206428
RN  - EC 2.7.1.1 (MTOR protein, human)
RN  - EC 2.7.11.1 (Ribosomal Protein S6 Kinases, 70-kDa)
RN  - EC 2.7.11.1 (TOR Serine-Threonine Kinases)
RN  - W36ZG6FT64 (Sirolimus)
SB  - IM
MH  - *Carcinoma, Squamous Cell/genetics/metabolism
MH  - Cell Line, Tumor
MH  - Cell Proliferation
MH  - Humans
MH  - Ribosomal Protein S6 Kinases, 70-kDa
MH  - Sirolimus
MH  - *TOR Serine-Threonine Kinases/metabolism
MH  - *Tongue Neoplasms/genetics/metabolism
EDAT- 2018/10/20 06:00
MHDA- 2020/08/08 06:00
CRDT- 2018/10/20 06:00
PHST- 2018/03/21 00:00 [received]
PHST- 2018/09/12 00:00 [revised]
PHST- 2018/09/12 00:00 [accepted]
PHST- 2018/10/20 06:00 [pubmed]
PHST- 2020/08/08 06:00 [medline]
PHST- 2018/10/20 06:00 [entrez]
AID - S0278-2391(18)31090-5 [pii]
AID - 10.1016/j.joms.2018.09.020 [doi]
PST - ppublish
SO  - J Oral Maxillofac Surg. 2019 Sep;77(9):1928-1940. doi: 
      10.1016/j.joms.2018.09.020. Epub 2018 Sep 24.